Ori Biotech Ltd

Ori Biotech Ltd is a biotechnology company that focuses on enhancing cell and gene therapy manufacturing through its innovative IRO® platform, aimed at improving production efficiency and quality. Founded in 2015 and headquartered in London, UK, Ori Biotech Ltd specializes in the development of advanced manufacturing processes for cell and gene therapies. The company has successfully completed 3 funding rounds, with the most recent being a Series B round on January 18, 2022, raising GBP 75. 92 million from investors including Chimera Investment Corporation and Novalis LifeSciences.

The CEO, Jason Foster, leads the company, which was founded by Farlan Veraitch. Ori Biotech Ltd specializes in advancing the manufacturing processes of cell and gene therapies through its core product, the IRO® platform. This cloud-native solution is designed to enhance biological performance while maintaining the benefits of automation, effectively addressing the challenges of high manufacturing costs, low throughput, and variability that plague the industry. The IRO® platform streamlines the development and manufacturing processes, enabling scientists to achieve high-quality cell production essential for successful patient outcomes.

Ori Biotech's products cater to a diverse client base that includes Contract Development and Manufacturing Organizations (CDMOs), healthcare providers, and research institutions focused on translating therapeutic innovations into scalable production. The company's solutions are marketed and utilized primarily in North America and Europe, targeting regions with advanced healthcare infrastructures and a growing demand for accessible gene therapies. Ori Biotech Ltd reported a revenue of GBP 131,857. 10 in the most recent year, 2023.

The company operates with a focus on partnerships with CDMOs and commercial manufacturers, engaging in long-term agreements where clients utilize the IRO® platform for their manufacturing needs. These partnerships may involve subscription-based access to the IRO® platform and necessary consumables, reflecting the value provided through increased efficiency and reduced production costs. In January 2022, Ori Biotech Ltd raised GBP 75. 92 million in Series B funding, with plans to expand its personnel across all functions to support the transition to pre-commercialization and the launch of its CGT manufacturing platform.

The company aims to enhance its product offerings and expand into new markets, particularly focusing on regions with growing demand for gene therapies. The funding will facilitate these initiatives, helping Ori Biotech to tackle the manufacturing challenges faced in the industry.